Pipeline

OKYO’s lead drug candidate, urcosimod, is a novel, non-opioid, preservative-free eye-drop therapy with dual pain-relieving and anti-inflammatory activity for neuropathic corneal pain (NCP)

A Focus on Ocular Therapies

Pipeline

Urcosimod

Indication
Preclinical
IND
Phase 1
Phase 2
Phase 3

Neuropathic Corneal Pain (NCP)

Phase 2/3 Topline Data Expected Q2 2027

Phase 2/3 Topline Data Expected Q2 2027Phase 2

Rare Corneal Disease

TBD

TBDPreclinical

OK-201

Indication
Preclinical
IND
Phase 1
Phase 2
Phase 3

Discovery Program

Urcosimod Development Timeline